Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
Why now
Thesis: Clinical-stage biotech raises capital, diluting shareholders
Catalyst to watch: Use of proceeds and trial data readouts
Main risk: Dilution and convertible overhang weigh on shares
Why it matters
Upsized equity and convertible offering dilutes existing holders and signals capital need.
Details
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143...
Sources
- prnewswire · 2026-09-24 11:05 UTC